Key facts
as of Sep 2026- Wugen’s last known valuation is $245.0M (Aug 2025).
- It has raised $323.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($115.0M) in Aug 2025.
- Notable investors include Fidelity Management & Research Company, Alexandria Venture Investments, Alpha Wave Global, Sands Capital, BioGenerator Ventures — 13 tracked in total.
- 4 institutional filers report fund marks on Wugen across 72 filings.
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$2per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Wugen
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Wugen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 72 fair-value marks on Wugen between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAug 2025Later Stage VC (Series C)$115.0M▮
Dec 2022Early Stage VC (Series B)$172.0M▮
About Wugen
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. The company's technology offers engineered memory natural killer (NK) and CAR-T cell therapies derived from healthy donors, enabling clinicians to access consistent, ready-to-use treatments that reduce production time and support broader patient access.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2018
- Employees
- 64
- Website
- wugen.com/
- Ownership
- Privately Held (backing)